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Histone acetyltransferases (HATs) and deacetylases
(HDACs) function antagonistically to control histone
acetylation. As acetylation is a histone mark for
active transcription, HATs have been associated
with active and HDACs with inactive genes. We
describe here genome-wide mapping of HATs and
HDACs binding on chromatin and find that both are
found at active genes with acetylated histones. Our
data provide evidence that HATs and HDACs are
both targeted to transcribed regions of active genes
by phosphorylated RNA Pol II. Furthermore, the
majority of HDACs in the human genome function
to reset chromatin by removing acetylation at active
genes. Inactive genes that are primed by MLL-
mediated histone H3K4 methylation are subject to
a dynamic cycle of acetylation and deacetylation by
transient HAT/HDAC binding, preventing Pol II from
binding to these genes but poising them for future
activation. Silent genes without any H3K4 methyla-
tion signal show no evidence of being bound by
HDACs.
INTRODUCTION
Histone acetylation plays key roles in modulating chromatin
structure and function (Shahbazian and Grunstein, 2007). The
acetylation state of a given chromatin locus is controlled by
two classes of antagonizing histone modifying enzymes, histone
acetyltransferases (HATs) and deacetylases (HDACs), which add
or remove acetyl groups to/from target histones, respectively.
Acetylation is generally associated with transcriptional activa-
tion, and several HATs have been identified as transcription co-
activators, including GCN5, PCAF, CBP, p300, Tip60, and MOF
(reviewed in Roth et al., 2001; Yang, 2004a). In contrast, histone
deacetylation is generally associated with transcriptional repres-
sion, and HDACs have been identified as transcriptional
corepressors (Kadosh and Struhl, 1997; Rundlett et al., 1998;
Taunton et al., 1996). These enzymes are highly conservedfrom yeast to human. Based on their homology with yeast ortho-
logs and other phylogenetic analyses, the 18 HDACs in humans
can be grouped into four classes: class I (HDAC1, 2, 3, and 8with
a homology to Rpd3), class II (HDAC4, 5, 6, 7, 9, and 10 with a
homology to Hda1), class III (Sirt1, 2, 3, 4, 5, 6, and 7 with
a homology to Sir2), and class IV (HDAC11) (de Ruijter et al.,
2003; Yang and Gregoire, 2005; Yang and Seto, 2008). Similar
to HATs, HDACs have critical functions in many cellular path-
ways, and their misregulation has been linked to multiple
cancers. Chemicals that inhibit HDAC activity are currently
among the most promising drugs in anticancer therapies.
Corepressor HDACs are traditionally considered to repress/
inhibit transcription by associating with gene promoters and
are replaced by stimulating coactivator HATs for subsequent
activation upon signal transduction (Berger, 2007; Xu et al.,
1999). Histone acetylation has been suggested to play roles in
both transcriptional initiation and elongation. Acetylation of
nucleosomes surrounding transcription start sites (TSSs) may
stabilize the binding of other chromatin remodeling factors
at promoter regions (Hassan et al., 2001) and/or destabilize
nucleosome structure (Boeger et al., 2003; Reinke and Horz,
2003), which may lead to decreased nucleosome occupancy
immediately upstream of TSSs and facilitate RNA Pol II binding
(Schones et al., 2008). Nucleosomes also present formidable
barriers to the passage of Pol II during transcriptional elongation
(Orphanides et al., 1998). Global acetylation in transcribed
regions is required for increased levels of basal transcription in
yeast (Govind et al., 2007; Vogelauer et al., 2000). Consistent
with these genetic and biochemical results, genome-wide loca-
tion analysis in yeast found that HAT binding is correlated with
transcriptional activation (reviewed by Shahbazian and Grun-
stein, 2007). However, the mode of association of the transcrip-
tional corepressors, HDACs, with gene expression in yeast has
been a topic of debate. Some studies suggested they are asso-
ciated with gene repression (Kadosh and Struhl, 1997; Robert
et al., 2004; Xie et al., 1999), while others found they are elevated
in active genes (Kurdistani et al., 2002; Wang et al., 2002).
Currently, little is known about the genome-wide profiles of
HDACs in higher eukaryotic organisms. While genome-wide
profiling of HATs in mammalian systems has been performed,
the data are limited. Genome-wide analysis of TAF1 binding
confirmed its promoter localization (Kim et al., 2005); anotherCell 138, 1019–1031, September 4, 2009 ª2009 Elsevier Inc. 1019
HAT, p300, may be associated with both promoters and
enhancers (Heintzman et al., 2007; Visel et al., 2009).
Our previous genome-wide mapping has revealed numerous
combinatorial patterns of histone modifications in human CD4+
T cells (Barski et al., 2007; Wang et al., 2008) and suggested
that modification patterns can indicate differentiation potential
of cells (Cui et al., 2009; Wei et al., 2009; reviewed in Wang
et al., 2009). To understand the mechanisms of pattern estab-
lishment and the specificity of various HATs and HDACs, we
decided to systematically determine the genomic locations of
these enzymes in human CD4+ T cells. Surprisingly, we found
that the binding for all HATs (CBP, p300, PCAF, Tip60, MOF)
and HDACs (HDAC1, HDAC2, HDAC3, HDAC6) analyzed is posi-
tively correlated with gene expression, Pol II binding, and acety-
lation levels. The p300 and CBP HATs are associated with
enhancers and promoters, whereas MOF, PCAF, and Tip60 are
elevated in transcribed regions in addition to promoters of active
genes. Our data suggest that HDAC6, previously believed to
function mainly in the cytoplasm, is targeted to chromatin of
active genes. Interestingly, HDAC6 and Tip60 may be recruited
to active genes, possibly through direct interaction with phos-
phorylated RNA Pol II. Inhibition of HDAC activities revealed
two major roles of HDACs: (1) removal of acetyl groups at active
genes added by HATs during transcriptional initiation and elon-
gation to maintain an adequate level of acetylation that may
support specific transcriptional elongation but inhibit promis-
cuous initiation, and (2) removal of acetyl groups added
by transient binding of HATs at inactive gene promoters to main-
tain a reduced level of acetylation and to prevent Pol II from
binding. Knockdown of WDR5, an essential subunit of the MLL
complexes, indicated that H3K4 methylation primes the chro-
matin of a subset of silent genes and facilitates histone acetyla-
tion, thus providing large-scale support for the crosstalk between
histonemodifications.Our results suggest that the dynamic cycle
of acetylation and deacetylation by the transient binding of HATs
andHDACs, together with prior H3K4methylation,may poise the
primed genes for future activation.
RESULTS
Mapping the Genome-wide Distribution of HATs
and HDACs
We have performed chromatin immunoprecipitation combined
with high-throughput sequencing (ChIP-Seq) experiments for
five HATs (p300, CBP, MOF, PCAF, and Tip60) and four HDACs
(HDAC1, HDAC2, HDAC3, and HDAC6) using chromatin
prepared from human primary resting CD4+ T cells as described
previously (Barski et al., 2007). These HATs and HDACs were
chosen because they are expressed in human T cells and
specific antibodies are available for them. To stabilize HATs/
HDACs on chromatin, we first treated cells with bifunctional
membrane-permeating crosslinker, disuccinimidyl glutarate
(DSG), to preserve the protein-protein association (Tian et al.,
2005) before formaldehyde crosslinking. All the antibodies
were validated using immunoblotting assays (Figure S1 and
Table S1 available online) and the ChIP DNA samples resulting
from these antibodies were confirmed with qPCR assays. To
gain further confidence in our ChIP-Seq data for these modifying1020 Cell 138, 1019–1031, September 4, 2009 ª2009 Elsevier Inc.enzymes, we compared our data with published binding sites for
p300 in the literature (Table S2) and confirmed selected sites with
qPCR assays (Figures S2 and S3).
HATs Are Enriched in Active Genes and Correlated
with Gene Expression
CBP and p300 are structurally highly homologous and function-
ally redundant (Roth et al., 2001). Both enzymes are tumor
suppressors and function as integrators for many signal trans-
duction pathways through interaction with numerous critical
transcription factors and other functional proteins. Our data indi-
cate that p300 is highly enriched in promoters (Figure 1A) and
potential enhancers identified by intergenic DNase I hypersensi-
tive (HS) sites (Figure 1B). The latter is consistent with recent
reports that acetylation islands (Roh et al., 2007) and p300
binding sites (Visel et al., 2009) can be used to predict functional
enhancers. As expected, CBP demonstrated a global distribu-
tion pattern very similar to p300 in promoters and enhancers
(Figures 1A and 1B). These data are consistent with a role for
these enzymes in transcriptional initiation (Cho et al., 1998).
We found that 8707 promoters are associated with one or both
of these enzymes. Although p300 and CBP are highly homolo-
gous, 222 promoters were associated with only p300 and 2747
were associated with only CBP, whereas 5738 promoters asso-
ciated with both (Figure S4A). The differential target genes of
p300 and CBP may explain their functional differences.
PCAF (p300/CBP associated factor) and GCN5 are another
pair of highly homologous HATs in mammals (reviewed by
Yang, 2004b). In addition to histone acetylation activity, the bro-
modomains of GCN5 and PCAF can bind acetylated N-terminal
tails of histone H3 and H4 (Dhalluin et al., 1999). Thus, they act as
both acetylation ‘‘producers’’ and ‘‘effectors.’’ Similar to p300
and CBP, PCAF was highly enriched in promoters of active
genes (Figure 1A). PCAF appears to be relatively more enriched
in gene body regions as compared to CBP and p300 (Figure 1A),
which is consistent with the proposed function of PCAF in
transcriptional elongation (Cho et al., 1998). The binding of
PCAFwas also elevated in intergenic DNase HS sites (Figure 1B),
suggesting that it may also be involved in enhancer activities.
Interestingly, 76.4% and 92.9% of genes associated with PCAF
in promoter regions were also bound by p300 and CBP, respec-
tively, in the promoter regions (Figures S4B and S4C).
MOF and Tip60 belong to the MYST family of HATs that are
less characterized and more diverse than the CBP/p300 and
GCN5/PCAF HAT families (Yang, 2004b). Tip60 is the catalytic
subunit of an evolutionarily conserved complex, which contains
at least 12 subunits, including TRRAP (Doyon et al., 2004). It has
been implicated in multiple roles in transcription, DNA damage
repair, and cell-cycle regulation, as well as being linked to
many diseases. MOF is the catalytic subunit of an evolutionarily
conserved MSL complex that is involved in dosage compensa-
tion and gene expression in Drosophila, though the functional
role of the human MSL complex remains to be determined
(Rea et al., 2007). Tip60 can acetylate H2AK5, H3K14, and
H4K5, K8, K12, K16 (Ikura et al., 2000), whereas both Drosophila
and human MOF are specific for H4K16 acetylation (Dou et al.,
2005). We found that MOF was detected at high levels at the
promoter region and was also relatively more enriched in gene
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Figure 1. All HATs Are Correlated with Gene Expression, Pol II, and Acetylation Levels
(A) Profiles of HATs binding across 50 gene ends, 30 gene ends, and gene body regions of the 1000most active, intermediately active, and least active genes were
examined with ChIP-Seq. txStart, transcription start site; txEnd, transcription end site.
(B) Profiles of HATs binding across intergenic (5 kb away from any gene) or promoter (defined as ± 1 kb surrounding TSS) DNase HS sites. DNase HS sites were
obtained from Boyle et al. (2008).
(C) Correlation between HAT binding and gene expression levels. Genes were grouped to 100 gene (one dot in the figure) sets according to expression level. The
HAT binding level in promoter region was calculated for the same 100 gene sets. The y axis indicates the HAT binding level, and the x axis indicates the expression
level.
(D) Correlation between HAT binding and RNA Pol II binding levels among the 100 gene sets grouped according to expression levels as defined in (C). The y axis
indicates the HAT binding level, and the x axis indicates the Pol II level.
(E) Correlation between HAT binding and histone acetylation levels among the 100 gene sets grouped according to expression levels as defined in (C). The acet-
ylation level was calculated by pooling all reads for 16 histone acetylations in H3 and H4 mapped previously (Wang et al., 2008). The y axis indicates the HAT
binding level, and the x axis indicates the acetylation level.body region as compared to CBP and p300 (Figure 1A), which is
different from the DrosophilaMOF that shows a bimodal binding
at promoters and 30 ends of genes (Kind et al., 2008). Similarly,
Tip60 exhibits strong binding at both the promoter and within
the gene body of active genes (Figure 1A). These data areconsistent with the elevated H4K16 acetylation along gene
bodies of active genes (Wang et al., 2008) and with a role for
Tip60 in transcriptional elongation. MOF and Tip60 were de-
tected at 8025 and 6797 genes, respectively, with an overlap
of 5462 genes between them (Figure S4D). MOF and Tip60Cell 138, 1019–1031, September 4, 2009 ª2009 Elsevier Inc. 1021
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Figure 2. HDACs Are Positively Correlated with Gene Expression, Pol II Binding, and Acetylation Levels
(A) Profiles of HDAC binding across 50 gene ends, 30 gene ends, and gene body regions of 1000 most active, intermediately active, and silent genes.
(B) Profiles of HDAC binding across intergenic or promoter DNase HS sites.
(C) Correlation between HDAC binding and gene expression levels. See Figure 1C for details.
(D) Correlation between HDAC binding and RNA Pol II binding levels. See Figure 1D for details.
(E) Correlation between HDAC binding and histone acetylation levels. See Figure 1E for details.also showed similar binding patterns at both the promoters and
intergenic DNase HS sites (Figure 1B).
The higher levels of HATs in active genes suggest that they
may be positively correlated with gene activity. This was indeed
confirmed by the analysis of average gene expression and
average HAT ChIP-Seq read counts at promoters (Figure 1C).
Interestingly, our data indicate that all the HATs are positively
correlated with RNA Pol II binding (Figure 1D). As expected,
we also observed positive correlation between HAT binding
and histone acetylation levels (Figure 1E).
In summary, our data indicate that p300 and CBP are mainly
targeted to promoters and enhancers, whereas PCAF, MOF,
and Tip60 are also associated with transcribed regions of active
genes in addition to promoters. These data are consistent with
the notion that p300 and CBP are involved in transcriptional initi-
ation, while PCAF, MOF, and Tip60 may also be involved in tran-
scriptional elongation. We also find that even though homolo-
gous HATs can bind to distinct sets of genes, many genes are
associated with multiple HATs (for example in the NFkB and1022 Cell 138, 1019–1031, September 4, 2009 ª2009 Elsevier Inc.CD69 genes shown in Figures S2 and S3), suggesting that they
may function collaboratively, sequentially, or independently at
the same target genes.
HDACs Are Associated with Active Genes and Positively
Correlated with Transcription
HDACs are generally believed to act as transcriptional corepres-
sors (Berger, 2007; Li et al., 2007). It has been traditionally
believed that HDACs are bound to repressed genes and are re-
placed by HATs upon gene activation (Xu et al., 1999). However,
little is known about their target gene specificity in the human
genome. Our data revealed that all the HDACs analyzed,
including class I HDACs HDAC1, HDAC2, and HDAC3 and class
II HDAC HDAC6, were enriched in active genes but not silent
genes (Figure 2A). HDAC1 and HDAC3 were mainly detected in
promoter regions, whereas HDAC2 and HDAC6 were elevated
in both the promoter and gene body regions of active genes.
We also examined their presence at potential enhancers and
found that HDAC1, 3, and 6 were mainly enriched in promoter
DNase HS sites, whereas HDAC2was highly elevated in both the
intergenic and promoter DNase HS sites (Figure 2B).
Our observation of the association of HDAC6 with chromatin
was unexpected because it is believed to be predominantly
cytoplasmic (reviewed in Boyault et al., 2007). The in vivo histone
deacetylase activity of HDAC6 has not been demonstrated,
though it has strong activity in vitro. Our data that HDAC6 was
detected in nuclear extracts (Figure S1) and highly enriched in
chromatin of 4706 active genes (Figure 2) strongly suggest that
it functions to deacetylate histones in vivo.
The enrichment of these HDACs in active genes suggests
that they may be positively associated with gene expression.
Indeed, we found that all HDACs tested were positively corre-
lated with messenger RNA (mRNA) expression levels (Figure 2C)
and Pol II levels (Figure 2D). Interestingly, HDAC levels also ap-
peared to positively correlate with histone acetylation levels
(Figure 2E).
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Figure 3. Tip60 and HDAC6 Are Recruited to Active
Genes through Interaction with Phosphorylated RNA
Polymerase II
(A) Distribution profiles of HDAC6, Tip60, Pol II, and
H3K36me3 across the active genes were plotted. The left y
axis indicates tag densities for HDAC6, Tip60, and Pol II.
The right axis indicates tag density for H3K36me3.
(B) Coimmunoprecipitation of TRRAP with RNA Pol II. Nuclear
extracts (Input) and immunoprecipitates with control IgG or
Pol II antibodies were resolved by SDS-PAGE and blotted
with antibodies against TRRAP. The size markers are indi-
cated on the left of the panel. The band corresponding to
TRRAP is indicated on the right.
(C) Coimmunoprecipitation of phosphorylated RNA Pol II with
TRRAP. The band corresponding to phosphorylated Pol II is
indicated on the right.
(D) Coimmunoprecipitation of phosphorylated RNA Pol II with
HDAC6. The band corresponding to phosphorylated Pol II is
indicated on the right.
In summary, our data confirmed the expectation
that HATs, as transcription coactivators, are highly
enriched in active genes (Figures 1 and S5).
Surprisingly, we found that HDACs are also highly
enriched in active genes (Figure 2). The majority
of HDACs in the human genome are associated
with active genes, and only a minor fraction are de-
tected in silent genes (Figure S5). This observation
suggests that one major function of HDACs is to
remove the acetyl group added by HATs in active
genes and to reset chromatin modification after
gene activation, as suggested previously for Hos2
(Wang et al., 2002).
Tip60 and HDAC6 May Be Targeted to
Active Genes through Interaction with
Phosphorylated CTD of RNA Polymerase II
We noticed that both Tip60 and HDAC6 are highly
elevated in the transcribed regions of active genes
(Figure S3). The targeting of the yeast Rpd3 deace-
tylase complexes to the transcribed gene body
regions has been suggested to be mediated by H3K36 methyla-
tion through the chromodomain of the Eaf3 subunit (Carrozza
et al., 2005; Joshi and Struhl, 2005). However, one human
homolog of Eaf3, the MORF4 protein, lacks the chromodomain
(Carrozza et al., 2005), suggesting that the mammalian HDAC
complexes may use different targeting mechanisms. Indeed,
our data indicate that the distribution profiles of both Tip60 and
HDAC6 in the gene body region appeared to parallel the signals
of Pol II more than the signals of H3K36me3 (Figure 3A). There-
fore, we hypothesized that Tip60 and HDAC6 may physically
interact with Pol II, thus being recruited to transcribed regions
in the human genome. To test this hypothesis, we examined
whether they can be coimmunoprecipitated with Pol II. However,
the antibodies against Tip60 failed to pull down Pol II (data not
shown). We reasoned that the antibody binding might inhibit
the interaction between Tip60 andPol II. Therefore, we examined
the reciprocal interaction of Pol II with TRRAP, which is a coreCell 138, 1019–1031, September 4, 2009 ª2009 Elsevier Inc. 1023
Figure 4. Recruitment of Tip60 and HDAC6 by TCR Signaling Is Correlated with the Recruitment of RNA Pol II
(A) The changes in Pol II, Tip60, and HDAC6 binding after TCR signaling determined by ChIP-Seq (y axis) are plotted against the changes in expression levels (x
axis). Genes were grouped to 100 gene sets as one dot in the figure.
(B) The changes in Tip60 and HDAC6 binding levels after TCR signaling are plotted against the changes in Pol II binding level.subunit of the Tip60 complex (Ikura et al., 2000). As shown in
Figure 3B, TRRAP was coimmunoprecipitated with Pol II. Inter-
estingly, we found that only the phosphorylated Pol II was coim-
munoprecipitated with TRRAP (Figure 3C). Similarly, we only de-
tected the phosphorylated form but not the unphosphorylated
form of Pol II from the immunoprecipitates with anti-HDAC6 anti-
bodies (Figure 3D), though we failed to detect HDAC6 from Pol II
immunoprecipitates (data not shown).We believe this interaction
is specific, or else we expect to also detect the nonphosphory-
lated form of Pol II (lower band 220 KDa). Therefore, we conclude
that Tip60 and HDAC6 may be recruited to the transcribed
regions of active genes through a different mechanism from
yeast by directly or indirectly interacting with elongating Pol II.
HATs and HDACs Are Targeted to Activated Genes upon
TCR Signaling
If Tip60 andHDAC6 are recruited by elongating Pol II, the change
in Pol II binding should lead to a corresponding change in Tip60
andHDAC6 binding. To test this hypothesis, we activated resting
T cells with anti-CD3 and anti-CD28 antibodies and analyzed the
changes in gene expression, Pol II, Tip60, and HDAC6 binding.
As shown in Figure 4A, the fold changes in read counts of all
these enzymes demonstrated a positive correlation with that of
gene expression. Interestingly, both the changes in Tip60 and
HDAC6 binding also exhibited a positive correlation with that
of Pol II upon TCR signaling (Figure 4B). These data are consis-
tent with the observation that Tip60 and HDAC6 physically
interact with Pol II, further supporting the notion that Tip60
and HDAC6 are recruited to transcribed regions of active genes
by interacting with elongating Pol II.1024 Cell 138, 1019–1031, September 4, 2009 ª2009 Elsevier Inc.HDACs Function to Control Acetylation Levels
in Active Genes
The HDACs recruited to active genes by Pol II may function to
remove the acetylation added during gene activation by HATs.
To test this hypothesis, we inhibited HDAC activities with the
HDAC inhibitors trichostatin A (TSA) and Butyrate and examined
the genome-wide changes in H3K9ac and H4K16ac with ChIP-
Seq. Indeed, we observed remarkable increases in both H3K9
and H4K16 acetylation in active genes when resting T cells
were treated with TSA + Butyrate, as exemplified for the CD4
locus (Figure 5A). Because both Pol II and HDACs are enriched
much more in active genes than in inactive genes, particularly
in the promoter and downstream of TSS regions (Figures 1,
2,5B, and 5C), inhibition of HDAC activities should result in
increased acetylationmore in active genes than in inactive genes.
Indeed, our data revealed that the highest increase in both
H3K9ac and H4K16ac was detected in active genes, especially
in regions surrounding the TSS (Figures 5D and 5E). Therefore,
we conclude that HDACs recruited to active genes are functional
and act to control the acetylation level together with the HATs.
HDAC Inhibitor Treatment Reveals Poised Genes
HDACs have been suggested to function as transcriptional core-
pressors and associate with repressed genes (Berger, 2007; Li
et al., 2007). However, our ChIP-Seq data did not reveal high
levels of binding of HDACs to silent genes (Figure 2), suggesting
that they may not stably bind to their target genes of repression.
To understand the functional roles of HDACs in gene silencing,
we examined the histone acetylation patterns of silent genes
with TSA + Butyrate treatment. Interestingly, we found that
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Figure 5. Inhibition of HDAC Activities Leads to Further Increases of Acetylation Levels in Active Genes
(A) HDAC inhibitor treatment causes remarkable increases in histone acetylation in active genes. Resting T cells were treated with TSA and Butyrate and the
distribution of H3K9ac and H4K16ac was analyzed using ChIP-Seq. The acetylation pattern of the CD4 locus is shown as custom tracks on the UCSC genome
browser. TSA+Bu, cells were treated with TSA and Butyrate.
(B) Pol II is highly enriched in the promoter and downstream of TSSs of active genes. The profiles of Pol II binding surrounding TSSs are shown for active, inter-
mediately active, and silent genes.
(C) HDAC6 is highly enriched in the promoter and downstream of TSSs of active genes. The profiles of HDAC6 binding surrounding TSSs are shown for active,
intermediately active, and silent genes.
(D) The most increase in H3K9 acetylation is detected in the promoter and downstream of TSSs of active genes. Act:0h, Act:2h, Sil:0h, and Sil:2h indicate the
normalized acetylation levels of the active genes and silent genes with TSA treatment (2 hr) or no treatment (0 hr).
(E) The most increase in H4K16 acetylation is detected in the promoter and downstream of TSSs of active genes.a subset of silent genes exhibited a remarkable increase in
acetylation, as demonstrated for the FOSL1 gene (Figure 6A).
However, examination of HAT and HDAC binding with the
ChIP-Seq data revealed no high level binding of HDACs in inac-
tive genes (Figure 2A and the region highlighted in the red box in
Figure 6B). Therefore, the remarkable increase in acetylation in
the presence of HDAC inhibitors suggests that these genes are
subject to constant acetylation and deacetylation cycles, likely
through transient and unstable binding of HATs and HDACs.
To test this hypothesis, we examined the binding of HATs and
HDACs to the FOSL1 promoter by using qPCR analysis of
ChIP DNA. We detected low but reproducible binding of both
HATs and HDACs to this region (Figure 6C). The rapid increase
in acetylation in as short as 10 min in the presence of HDAC
inhibitors (Figure 6A) suggests that HATs frequently but tran-
siently visit the promoters to add acetyl groups to histones and
that HDACs keep removing these acetylation signals to maintain
the repression of these genes. This dynamic cycle of acetylation
and deacetylation by transient binding of HATs and HDACs may
poise the genes for future activation. To test whether this is the
case, we identified 167 genes, which were induced by TCR
signaling in CD4+ T cells, and examined their histone acetylation
profiles with the HDAC inhibitor treatment. We found a remark-
able increase in both H4K16ac (Figure 6D) and H3K9ac(Figure S6) in the presence of HDAC inhibitors. In summary,
our data indicate that HATs can transiently and frequently bind
to the nonexpressed genes to acetylate the histones; HDACs
also bind transiently and frequently to remove the acetyl group
and keep the genes inactive. The concerted action of HATs
and HDACs poises these genes for future activation.
H3K4 Methylation Facilitates Histone Acetylation
To attempt to understand the differences between the silent
genes that became acetylated and those that did not in the pres-
ence of the HDAC inhibitors, we examined the methylation
patterns, and we found that the former was associated with
H3K4 methylation and H2A.Z, whereas the latter was not (Fig-
ure S7). To confirm this on a genome-wide scale, we identified
a total of 5703 silent gene promoters that were not associated
with significant H4K16ac and examined their acetylation after
HDAC inhibitor treatment. Interestingly, 73% of the 1776
promoters associated with H3K4 mono-, di-, and trimethylation
acquired significant levels of H4K16ac, whereas only 0.5% of
the 3927 promoters not associated with H3K4 methylation
became acetylated at H4K16 (Figure 6E). Similarly, among the
5224 promoters that did not exhibit H3K9ac before the TSA
treatment, 61% of the 1179 promoters with H3K4 methylations
became acetylated, whereas only 0.4% of the 4045 promotersCell 138, 1019–1031, September 4, 2009 ª2009 Elsevier Inc. 1025
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Figure 6. HATs and HDACs Function at Silent Genes Primed by H3K4 Methylation
(A) Rapid increase of histone acetylation in the silent gene FOSL1 caused by HDAC inhibitor treatment. ChIP assays were performed using H3K9ac and H4K16ac
antibodies with chromatin from cells treated in the absence or presence of HDAC inhibitors. The ChIP DNA was analyzed by qPCR.
(B) The ChIP-Seq signals for the IL7R gene (active) and FOSL1 gene (silent) were displayed. The signals highlighted in the red box are not statistically significant as
determined using SICER (Zang et al., 2009).
(C) qPCR assays revealed low but reproducible binding of HATs and HDACs in the silent FOSL1 promoter (see B).
(D) H4K16ac was strongly elevated in the TCR-inducible genes by TSA + Butyrate treatment. H4K16 acetylation was profiled using ChIP-Seq in resting T cells in
the presence or absence of TSA + Butyrate treatment. The H4K16ac profiles were plotted for the 167 silent genes that are induced by TCR signaling.
(E) The presence of H3K4 methylation indicates the potential of histone H4K16 acetylation. All silent genes (5703) not associated with H4K16ac were separated
into the genes with H3K4 methylation (1776) and those without (3927). The number of genes that became acetylated with the HDAC inhibitor treatment was
examined for each group (shown by the red bar).
(F) The presence of H3K4 methylation indicates the potential of histone H3K9 acetylation. All silent genes (5224) not associated with H3K9ac were grouped and
analyzed similarly as in (E). The number of genes that became acetylated is shown by the red bar.
(G) Knockdown of WDR5 decreased H3K4me3 signals in the promoter regions. H3K4me3 distribution in wild-type and knockdown cells were determined using
ChIP-Seq, and the profiles were analyzed as in Figure 1.1026 Cell 138, 1019–1031, September 4, 2009 ª2009 Elsevier Inc.
without H3K4 methylation became acetylated at H3K9 after the
TSA treatment (Figure 6F). These results strongly suggest that
H3K4 methylation facilitates the histone acetylation events.
To test this hypothesis directly, we knocked down WDR5,
which is an essential subunit of the MLL complexes that are
responsible for H3K4me2 and H3K4me3 modifications (Wy-
socka et al., 2005). The H3K4me3 level was significantly
decreased in HeLa cells transfected with a vector expressing
a short hairpin RNA (shRNA) targeting WDR5 as compared to
cells transfected with a control vector (Figures S8A and S8B).
ChIP-Seq analysis revealed that the overall H3K4me3 binding
decreased about 2-fold in the knockdown cells (Figure 6G). To
determine whether inhibition of H3K4 methylation leads to
changes in histone acetylation, we treated the HeLa cells trans-
fectedwith the siRNA or control vector with TSA +Butyrate for 60
min, and we analyzed the genome-wide distribution of H3K9ac
and H4K16ac using ChIP-Seq. First, we identified 325 genes
(group 1) that were associated with H3K4me3 in wild-type
HeLa cells but lost the modification in the knockdown cells. As
a control, we identified 409 genes (group 2) that showed less
than 10% change in the H3K4me3 level in the knockdown cells.
Among the group 1 genes, 40% exhibited an increase of at least
2-fold in H3K9ac in the control cells with the HDAC inhibitor
treatment, whereas only around 19% of these genes demon-
strated a similar increase in H3K9ac in the WDR5 knockdown
cells, which is a 50% decrease in gene number (Figure 6H). In
contrast, about 11% of the group 2 genes demonstrated an
increase in H3K9ac with the HDAC inhibitor treatment in the
control, and 14% of the group 2 genes showed an increase in
H3K9ac in the WDR5 knockdown cells (Figure 6H). A decrease
in H4K16ac was also observed in group 1 but not group 2 genes
with the HDAC inhibitor treatment (Figure S8C). These data indi-
cate that prior H3K4 methylation primes a subset of nonex-
pressed genes for histone acetylation in vivo. The fact that only
50% of the genes demonstrated decreases in H3K9ac could
be related with the possibility that H3K4me1 or H3K4me2
instead of H3K4me3 are present in some of the group 1 genes.
HDAC Inhibitor Treatment Leads to Increased Pol II
Binding at the Primed Genes
The transcription of the silent genes, which aremodified (primed)
by H3K4 methylation but not histone acetylation, may be
repressed by HDACs. Histone deacetylation may inhibit tran-
scription at the initiation and/or elongation step. If these genes
are bound by Pol II at promoters and the inhibition is at the elon-
gation step, HDAC inhibitor treatment, which induces a signifi-
cant increase in acetylation, should increase their mRNA levels.
Thus, we profiled the mRNAs in cells in the absence and pres-
ence of the HDAC inhibitors. Our data indicate that the HDAC
inhibitor treatment induced only two genes out of the 3449
‘‘true’’ silent genes that were associated with neither histone
acetylation nor H3K4 methylation. Interestingly, only 15 of the1382 genes primed by H3K4 methylation were induced by the
treatment, although most of them became highly acetylated in
the presence of HDAC inhibitors. These results suggest that
the repression of transcription by HDACs may occur at an earlier
step. To test this hypothesis, we analyzed Pol II binding in the
absence and presence of the HDAC inhibitors using ChIP-Seq.
Remarkably, we found that the HDAC inhibitor treatment
resulted in a significant increase in Pol II binding in the gene
promoters primed by H3K4 methylation but not in the silent
genes (Figures 7A and 7B). Among the 1358 inactive promoters
that were associated with H3K4 methylation but not Pol II, 420
(31%) and 814 (60%) became bound by Pol II after treatment
with the HDAC inhibitor for 2 and 12 hr, respectively. In contrast,
only 0.4% and 0.7% of the silent promoters not associated with
prior H3K4 methylation became bound by Pol II under these
conditions. Even though the primed promoters became bound
by Pol II after HDAC inhibitor treatment, they were not tran-
scribed, suggesting that transcriptional activation requires
further signals after Pol II binding in the promoter region. None-
theless, these results indicate that preventing Pol II binding is an
important step in the transcriptional repression by HDACs.
DISCUSSION
Drugswith the ability to inhibit HDAC activity are currently among
the most promising drugs in the treatment of cancer and other
diseases. However, the drug development community faces
significant challenges in the selection and design of drugs for
clinical candidates, partially because of the lack of known targets
of HATs and HDACs (Kazantsev and Thompson, 2008). Our
genome-wide distributions of HATs and HDACs provide new
clues for understanding the mechanisms for how HDAC inhibi-
tors work. For example, the efforts in understanding the func-
tional mechanisms of the drugs that inhibit HDAC6 have focused
on cytoplasmic proteins, including heat shock proteins or
a-tubulin (Kazantsev and Thompson, 2008). Hence, the nuclear
roles of HDAC6 associated with both primed and active genes
need to be considered for any further drug design and develop-
ment.
Distinct Functions of HATs and HDACs in Active
and Inactive Genes
Based on the binding patterns of HATs, HDACs, histone acetyla-
tion, and methylation, as well as the results from HDAC inhibitor
treatment, we propose that there are three major modes of asso-
ciation of HATs and HDACs in the genome.
Active Genes: Figure 7C
These genes are expressed and associated with histone methyl-
ation includingH3K4me1, 2, 3, aswell asH2A.Z in promoters and
H2BK5me1, H3K9me1, H3K27me1, H3K36me3, H3K79me1, 2,
3, and H4K20me1 in gene body regions (Barski et al., 2007;
Wang et al., 2008). We find that the highest levels of both HATs(H) Inhibition of H3K4me3 modification decreased H3K9ac with the HDAC inhibitor treatment. H3K4me3 and H3K9ac profiles were analyzed in the control (con)
and WDR5 knockdown (k.d.) cells. Group 1 genes lost H3K4me3 signals in the knockdown cells; group 2 genes did not show significant decrease in H3K4me3
signals in the knockdown cells. The y axis indicates the percentage of genes that showed an increase of at least 2-fold in H3K9ac with the HDAC inhibitor treat-
ment in both of these two gene groups.
Error bars indicate the standard deviation.Cell 138, 1019–1031, September 4, 2009 ª2009 Elsevier Inc. 1027
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Figure 7. HDACs Inhibit Pol II Binding to the Promoters Primed by H3K4 Methylation
(A) Promoters primed by H3K4 methylation become bound by Pol II after HDAC inhibitor treatment. Pol II binding levels were calculated by normalizing the Pol II
ChIP-Seq sequence reads in the promoter regions with the number of promoters.
(B) HDAC inhibitor treatment induces Pol II binding to the LMO4 promoter that was primed by prior H3K4 methylation.
(C) High levels of both HATs and HDACs are associated with active genes. HDACs function to reset chromatin by removing acetyl groups added by HATs
recruited by elongating Pol II.
(D) Low levels of both HATs and HDACs are associated with inactive genes primed by H3K4 methylation. HDACs function to repress transcription by preventing
Pol II binding by removing acetyl groups added by transient binding of HATs.
(E) No detectable levels of either HATs or HDACs are associated with silent genes devoid of any significant H3K4 methylation.andHDACs are detected in these genes and their binding is posi-
tively correlated with expression level and Pol II level. What is the
function of HDACs in these active genes? One possibility is that
chromatin modifications such as acetylation need to be reset
after transcription, as proposed previously (Wang et al., 2002).
HDACs are recruited to these genes to reset the chromatinmodi-
fication states andmaintain an adequate level of histone acetyla-1028 Cell 138, 1019–1031, September 4, 2009 ª2009 Elsevier Inc.tion, after the activities of Pol II and HATs. Indeed, our data indi-
cated that inhibition of HDAC activity through TSA + Butyrate
treatment caused increases in acetylation in the active genes
with the level of increase being correlatedwith theHDACbinding,
suggesting that HDAC recruitments to active genes function to
remove acetyl groups in active genes. Excessive histone acetyla-
tion in transcribed regions can destabilize chromatin and
increase cryptic initiation of transcription. It has been shown that
the Rpd3-containing complexes recruited by the H3K36 methyl-
ation signals after the RNA Pol II passage can deacetylate
histones and prevent cryptic transcriptional initiation in yeast
(Carrozza et al., 2005; Joshi and Struhl, 2005; Keogh et al.,
2005). Our data showing that HDAC6 physically interacts with
the elongating form of RNA Pol II and its distribution parallels
the Pol II but not the H3K36me3 signal suggest that the deacety-
lase is directly recruited to actively transcribed regions by RNA
Pol II and may bypass H3K36me3. Further experiments will be
needed to clarify the potentially different mechanisms employed
by different organisms.
Primed Genes: Figure 7D
Although these genes do not associate with significant histone
acetylation and are not expressed, they are associated with
H3K4methylation and H2A.Z. Even though our ChIP-Seq assays
did not reveal significant binding of either HATs or HDACs at
these genes, the more sensitive qPCR assays indicated binding
of these enzymes, albeit at relatively low levels. These data
suggest that HATs may bind transiently to these promoters
and add acetyl groups, which are then removed by the transient
binding of HDACs. Indeed, inhibition of HDAC activities resulted
in remarkable increases in acetylation in these promoters, sug-
gesting that the chromatin in these promoters is subject to
dynamic regulation by HATs and HDACs. The rapid removal of
the acetyl group by HDACs is consistent with a role in transcrip-
tional repression. Therefore, the cycle of transient acetylation
and deacetylation may keep these genes unexpressed but at
the same time maintain the promoters in a potentiated state for
future activation upon receiving external signals. There are at
least two potential mechanisms by which HDACs repress tran-
scription from these promoters: inhibition of Pol II binding to
the promoters and inhibition of Pol II elongation in the tran-
scribed regions. Our data revealed that HDAC inhibitor treatment
did not lead to either significantly increased Pol II levels in tran-
scribed regions or mRNA abundance; instead, it resulted in
a remarkable increase in Pol II levels in the promoter regions,
suggesting that a major step of transcriptional repression of
these genes by HDACs is the inhibition of Pol II binding to their
promoters.
Our data indicating that silent promoterswith prior H3K4meth-
ylation became substantially acetylated after the treatment with
HDAC inhibitors suggest that H3K4 methylation may prime the
chromatin structure and facilitate the acetylation process.
Indeed, knockdown ofWDR5,which downregulatedH3K4meth-
ylation, significantly decreased histone acetylation upon HDAC
inhibitor treatment. HowdoesH3K4methylation facilitate histone
acetylation? Previous in vitro studies have suggested that H3K4
methylation of nucleosome core particles can increase the effi-
ciency of acetylation by p300 (Wang et al., 2001). There are
several potential mechanisms by which H3K4 methylation can
promote histone acetylation (reviewed by Berger, 2007). First, it
recruits ATP-dependent chromatin remodeling complexes to
Chd1 (Pray-Grant et al., 2005) and NURF (Wysocka et al.,
2006), which opens chromatin to allowother histonemodification
enzymes to bind. Second, it is recognized directly by histone
acetylation complexes (Martin et al., 2006). In addition, the
MOF acetylase is recruited as a subunit of the MLL1 complexthat recognizes H3K4me2 and converts it to H3K4me3 (Dou
et al., 2005; Wysocka et al., 2005). Our data provide large-scale
experimental support that H3K4 methylation facilitates histone
acetylation and different histone modifications can act sequen-
tially or cooperatively.
Silent Genes: Figure 7E
These genes can be separated into two groups: one is associ-
ated with wide-spread H3K27me3 signals, which are added by
Polycomb group proteins, and the other does not associate
with any of the 40 modifications examined. Nonetheless, neither
of them shows detectable acetylation/deacetylation activities as
revealed by inhibition of HDAC activity and genome-wide
mapping of acetylation patterns. Therefore, these genes are
the least metabolically active in histone acetylation/deacetyla-
tion cycles.
In summary, our results reveal that there are two major roles
for HDACs. One is their function in active genes, where high
levels of HDACs act to remove the acetyl group added by high
levels of HATs during the process of transcriptional initiation
and elongation and reset the chromatin structure required for
the next round of transcription. The other is their function in
primed genes, where transient binding of HDACs removes the
acetyl group resulted from transient binding of HATs, maintains
a low level of acetylation, and prevents Pol II binding, thereby
maintaining promoters in an inactive state. In addition, we have
demonstrated that H3K4 methylation by the MLL complexes
primes a subset of nonexpressed genes for histone acetylation,
providing experimental support that these genes may be poised
by chromatin modification for future expression. Our data define
the division of labor for different HATs and HDACs and provide
a rich resource for further understanding of their function in tran-
scriptional regulation and genome function.
EXPERIMENTAL PROCEDURES
T Cell Purification, Chromatin Preparation, ChIP, and ChIP-Seq
HumanCD4+ T cells were purified fromblood as described before (Barski et al.,
2007; Wang et al., 2008). Resting T cells or cells activated with CD3 and CD28
antibody beads (Schones et al., 2008) were treated with 2 mM disuccinimidyl
glutarate (Sigma) for 45 min at room temperature to preserve the protein-
protein interactions, prior to the crosslinking with 1% formaldehyde at room
temperature for 10 min. Chromatin preparation, ChIP, and Solexa sequencing
were performed as described (Barski et al., 2007;Wang et al., 2008). Chromatin
templates from different donors were pooled and stored at80C. Six to eight
micrograms of antibodies were used for each ChIP experiment.
Coimmunoprecipitation, Immunoblotting, and Antibody Specificity
Jurkat cell nuclear extracts were prepared as described (Wang et al., 2008).
Coimmunoprecipitation (coIP) assays were performed as described (Cho
et al., 2007), with modifications (Supplemental Data). The specificity of each
antibody was tested by immunoblotting with Jurkat nuclear extracts. The anti-
bodies for coIP and ChIP-Seq were listed in Table S1.
HDAC Inhibitor Assay in Resting CD4+ T Cells and HeLa Cells
CD4+ T cells were resuspended in complete RPMI1640medium and incubated
in the presence of 100 ng/ml Trichostatin A (TSA, Sigma) and 2 mM Sodium
Butyrate for 0 hr, 10 min, 30 min, 1 hr, 2 hr, 4 hr, and 8 hr. HeLa cell were trans-
fected with a vector expressing an shRNA targeting WDR5 for 3 days before
the HDAC inhibitor treatment. Native chromatin from these cells was prepared
by Microccocal nuclease digestion as described (Barski et al., 2007; WangCell 138, 1019–1031, September 4, 2009 ª2009 Elsevier Inc. 1029
et al., 2008). ChIP assays were performed using chromatin from these cells
with anti-H3K9ac and -H4K16ac antibodies for ChIP-Seq and qPCR analysis.
Data Analysis
Sequence reads of mostly 25 bp were obtained using the Solexa Analysis
Pipeline. All reads were mapped to the human genome (hg18) and only
uniquely matching reads were retained. The output of the Solexa Analysis
Pipeline was converted to browser extensible data (BED) files detailing the
genomic coordinates of each read. Please see the Supplemental Data for iden-
tification of ChIP-enriched islands using SICER (Zang et al., 2009), HAT/HDAC
profiles across gene body and DNase HS regions, and correlation analysis
between HAT/HDAC binding and gene expression.
ACCESSION NUMBERS
We have deposited the short reads, BED files, and expression data sets in the
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